Perioperative Management of Parkinson's Disease

Perioperative Management of Parkinson's Disease: A Critical Care Perspective

Dr Neeraj Manikath , claude.ai

Abstract

Parkinson's disease (PD) affects approximately 1-2% of individuals over 65 years, and as this population ages, anesthesiologists and intensivists increasingly encounter these patients in perioperative settings. The physiological stress of surgery, enforced nil-per-os status, and potential drug interactions create a perfect storm for dopaminergic decompensation. This review synthesizes current evidence on critical aspects of perioperative PD management, with emphasis on dopaminergic medication timing, recognition and treatment of Parkinson's crises and neuroleptic malignant syndrome (NMS), and avoidance of contraindicated medications. Understanding these principles is essential for optimizing outcomes and preventing potentially fatal complications in this vulnerable population.

---

Introduction

Parkinson's disease is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss in the substantia nigra, resulting in the classic tetrad of resting tremor, rigidity, bradykinesia, and postural instability. Beyond motor symptoms, patients experience autonomic dysfunction, cognitive impairment, and altered pharmacokinetics that profoundly impact perioperative management.

The perioperative period presents unique challenges: surgical stress increases metabolic demands, fasting protocols interrupt established medication regimens, and common perioperative drugs may precipitate catastrophic neurological deterioration. Studies demonstrate that interruption of dopaminergic therapy for as little as 6-12 hours can trigger acute akinesia, while medication mismanagement contributes to increased postoperative complications, prolonged intensive care unit (ICU) stays, and mortality rates approaching 3-5% in severe cases.

This review provides evidence-based strategies for managing PD patients perioperatively, with practical pearls for critical care physicians.

---

Timing of Dopaminergic Medications

The Critical Window: Never Miss a Dose

Pearl #1: The golden rule of perioperative PD management is simple yet paramount: never abruptly discontinue dopaminergic medications. Levodopa has a plasma half-life of only 60-90 minutes, and interruptions as brief as 6 hours can precipitate acute akinetic crisis.

Preoperative Planning

Medication Reconciliation: Begin with comprehensive documentation of the patient's home medication regimen, including:

• All dopaminergic agents (levodopa/carbidopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors)
• Exact timing of doses (patients often have individualized schedules)
• Formulations (immediate-release vs. controlled-release)
• "Off" period characteristics

Hack #1: Schedule surgery early in the morning when possible, allowing patients to take their first medication dose with a small sip of water (≤30 mL) up to 1 hour before induction. This has been shown to reduce perioperative motor complications by up to 40%.

Intraoperative Strategies

The inability to administer oral medications during prolonged procedures necessitates alternative strategies:

Nasogastric/Orogastric Administration:

• For procedures >4 hours, place a nasogastric or orogastric tube for medication delivery
• Crush immediate-release levodopa/carbidopa tablets and suspend in 20-30 mL water
• Administer at the patient's usual intervals (typically every 3-4 hours for immediate-release formulations)
• Critical caveat: Never crush controlled-release preparations as this destroys the delivery mechanism and causes erratic absorption

Alternative: Rotigotine Transdermal Patch:

• Consider converting stable patients to rotigotine patch 24-72 hours preoperatively
• Provides continuous dopaminergic stimulation independent of enteral access
• Particularly valuable for emergency surgery or anticipated prolonged postoperative intubation
• Conversion ratios: approximately 1 mg rotigotine daily = 100 mg levodopa daily
• Oyster alert: Patches can cause significant skin reactions; rotate sites carefully

Apomorphine Rescue Therapy:

• Subcutaneous apomorphine (2-6 mg) provides rapid rescue for acute "off" episodes
• Onset within 10-20 minutes, duration 60-90 minutes
• Requires pretreatment with domperidone (not available in US) or trimethobenzamide to prevent severe nausea
• Contraindicated with 5-HT3 antagonists (ondansetron) - can cause profound hypotension

Postoperative Continuation

Pearl #2: Resume oral medications at the earliest possible moment. Even patients with ileus often tolerate small volumes of crushed levodopa/carbidopa.

Bridging Strategies:

• Continue nasogastric administration until reliable oral intake confirmed
• First oral dose should match patient's usual timing, not arbitrary hospital schedules
• Monitor for "wearing off" phenomena - patients may need more frequent dosing during acute illness
• Deep brain stimulation (DBS) devices should remain active throughout; verify functionality postoperatively

Hack #2: Create a "PD medication passport" card with exact medication schedule, emergency contact for patient's neurologist, and instructions for nursing staff. Attach to chart cover and medication administration record.

Special Considerations for MAO-B Inhibitors

Selegiline and rasagiline require special attention:

• Myth-busting: Contrary to historical teaching, MAO-B inhibitors at therapeutic doses do NOT cause hypertensive crisis with meperidine or sympathomimetics
• Safe to continue perioperatively
• Avoid meperidine specifically (serotonin syndrome risk), but other opioids are safe
• If discontinued preoperatively, allow 2-week washout before initiating serotonergic antidepressants

---

Managing Parkinson's Crises and Neuroleptic Malignant Syndrome

Parkinsonism-Hyperpyrexia Syndrome (Acute Akinesia)

Clinical Presentation:

Parkinsonism-hyperpyrexia syndrome (PHS), also called acute akinetic crisis, represents the most feared complication of dopaminergic withdrawal. Classic presentation includes:

• Profound akinesia or "frozen" state
• High fever (38.5-41°C)
• Altered mental status (confusion to coma)
• Severe rigidity ("lead pipe" or "plastic")
• Autonomic instability (labile blood pressure, tachycardia, diaphoresis)
• Elevated creatine kinase (CK) levels (often 1000-10,000 U/L)
• Leukocytosis
• Acute kidney injury from rhabdomyolysis

Oyster #1: PHS can be clinically indistinguishable from NMS, sepsis, or malignant hyperthermia. The key differentiator is temporal relationship to dopaminergic withdrawal vs. neuroleptic exposure.

Pathophysiology:

Abrupt reduction in nigrostriatal dopamine causes:

• Unregulated muscle contraction (rigidity, hyperthermia)
• Hypothalamic thermoregulatory dysfunction
• Rhabdomyolysis from sustained muscle activity
• Respiratory failure from chest wall rigidity

Management Protocol:

1. Immediate Restoration of Dopaminergic Therapy (first-line, definitive treatment):

   • Nasogastric levodopa/carbidopa: 100/25 mg every 2-3 hours initially
   • Consider higher doses (up to 200 mg levodopa q3h) for severe cases
   • Rotigotine patch: 8-16 mg/24h if enteral access unavailable
   • Apomorphine: 2-6 mg SC q2h as needed (with antiemetic premedication)

2. Supportive ICU Care:

   • Aggressive IV hydration (6-8 L/day) to prevent renal failure
   • Active cooling measures (cooling blankets, tepid sponging)
   • Continuous cardiopulmonary monitoring
   • Mechanical ventilation if respiratory failure ensues
   • Urinary alkalinization if myoglobinuria present

3. Adjunctive Therapies:

   • Amantadine: 100-200 mg IV or PO twice daily (NMDA antagonist with dopaminergic properties)
   • Bromocriptine: 2.5-10 mg PO/NG three times daily (direct dopamine agonist)
   • Dantrolene: 1-2.5 mg/kg IV every 6 hours (reduces rigidity by uncoupling excitation-contraction) - evidence is limited but considered in refractory cases
   • Benzodiazepines: Lorazepam 1-2 mg IV for severe agitation/rigidity

4. Avoid:

   • All neuroleptics (even "atypical" agents)
   • Physical restraints (worsen rigidity, hyperthermia, rhabdomyolysis)
   • Aggressive antipyretics alone (fever is centrally mediated, not hypothalamic)

Pearl #3: Response to treatment is typically gradual, occurring over 3-7 days. Mortality approaches 3-4% even with optimal management, rising to 20% if untreated.

Neuroleptic Malignant Syndrome in PD Patients

Clinical Context:

PD patients have heightened vulnerability to NMS due to depleted dopamine reserves. Even "safer" atypical antipsychotics can trigger NMS at standard doses.

Trigger Medications:

• Typical antipsychotics: Haloperidol, droperidol, chlorpromazine (highest risk)
• Atypical antipsychotics: Risperidone, olanzapine, ziprasidone, aripiprazole
• Antiemetics with antidopaminergic properties: Metoclopramide, prochlorperazine, promethazine
• Atypical triggers: Rarely, abrupt levodopa withdrawal can mimic NMS

Distinguishing NMS from PHS:

Feature	NMS	PHS
Trigger	Dopamine antagonist	Dopaminergic withdrawal
Onset	Hours to days after drug exposure	Days after medication interruption
Rigidity pattern	"Lead pipe" throughout	May be asymmetric initially
History	Recent neuroleptic exposure	Medication non-compliance/NPO status

Management Differences:

• NMS: Remove offending agent + supportive care + dopamine agonists
• PHS: Restore dopaminergic therapy + supportive care

Pearl #4: In ambiguous cases, assume BOTH conditions may coexist. Remove potential neuroleptic triggers AND restore dopaminergic therapy immediately.

Hack #3: ICU survival bundle for severe PHS/NMS:

1. Restore dopamine (levodopa q2-3h via NG)
2. Bromocriptine 5 mg TID
3. Amantadine 100 mg BID
4. Dantrolene 1 mg/kg q6h if CK >5000 or refractory rigidity
5. Target urine output >200 mL/hr
6. Consider therapeutic hypothermia (34-36°C) if temperature >40°C

---

Avoiding Contraindicated Antiemetics and Antipsychotics

The Dopamine Blockade Catastrophe

Postoperative nausea/vomiting (PONV) affects 30-50% of surgical patients, but standard antiemetic therapy can precipitate neurological disaster in PD patients. Similarly, ICU delirium management requires careful drug selection.

Absolutely Contraindicated Agents

High-Risk Dopamine Antagonists (NEVER USE):

1. Metoclopramide (Reglan):

   • Most commonly implicated perioperative medication error in PD
   • Crosses blood-brain barrier effectively
   • Can cause irreversible tardive dyskinesia even after single dose
   • Worsens rigidity, bradykinesia within hours
   • No safe dose in PD patients

2. Prochlorperazine (Compazine):

   • Potent central dopamine D2 antagonist
   • High extrapyramidal symptom (EPS) rate in normal patients (>20%)
   • Can trigger acute akinesia or NMS

3. Promethazine (Phenergan):

   • Significant antidopaminergic activity despite being antihistamine
   • Worsens motor symptoms

4. Haloperidol, Droperidol:

   • Extremely high affinity for D2 receptors
   • Historical use for PONV now obsolete in PD
   • Even low doses (0.625 mg) can cause severe rigidity
   • Droperidol "Black Box" warning includes increased risk in neurologically impaired patients

5. Typical Antipsychotics (chlorpromazine, fluphenazine, etc.):

   • Reserved for life-threatening agitation only
   • Immediate NMS risk

Moderate-Risk Agents (Use with Extreme Caution):

1. Atypical Antipsychotics:

   • Risperidone, Olanzapine: Significant D2 blockade at therapeutic doses; avoid if possible
   • Quetiapine: Lowest EPS risk among atypicals; acceptable at low doses (12.5-50 mg) for severe agitation/delirium
   • Aripiprazole: Partial D2 agonist; theoretically safer but case reports of motor worsening exist
   • Clozapine: Gold standard for PD-related psychosis but requires hematologic monitoring; not practical for acute perioperative use

2. Domperidone:

   • Peripheral dopamine antagonist (doesn't cross BBB effectively)
   • Not FDA-approved in USA; available in Europe/Canada
   • Safer than metoclopramide for gastroparesis but cardiac arrhythmia risk

Oyster #2: Many electronic prescribing systems do NOT flag these medications as contraindicated in PD. Always manually verify antiemetic orders.

Safe Alternatives for PONV Management

First-Line Safe Agents:

1. Ondansetron (Zofran):

   • 5-HT3 antagonist, no dopaminergic activity
   • Dose: 4-8 mg IV q8h
   • Caution: Contraindicated with apomorphine (severe hypotension)
   • Safe with all other PD medications

2. Granisetron, Palonosetron:

   • Alternative 5-HT3 antagonists
   • Longer half-life than ondansetron
   • Equally safe profile

3. Dexamethasone:

   • 4-8 mg IV at induction (single dose)
   • Anti-inflammatory mechanism, no dopaminergic effects
   • Synergistic with 5-HT3 antagonists
   • Concern: May worsen hyperglycemia, but generally safe

4. Scopolamine Transdermal:

   • Anticholinergic mechanism
   • Apply patch evening before surgery
   • Caution: Cognitive effects in elderly, may worsen confusion
   • Theoretically could improve tremor via anticholinergic effect

5. NK-1 Antagonists (Aprepitant, Rolapitant):

   • Neurokinin receptor antagonists
   • Excellent safety profile in PD
   • Expensive; typically reserved for high emetogenic risk (chemotherapy protocols)

Multimodal PONV Prophylaxis Strategy for PD Patients:

• Ondansetron 4 mg IV + Dexamethasone 4-8 mg IV at induction
• Total IV anesthesia (TIVA) preferred over volatile agents (lower PONV)
• Adequate hydration (minimize hypotension)
• Avoid nitrous oxide
• Regional anesthesia when feasible

Pearl #5: Prevention is superior to treatment. High-risk PD patients (major abdominal, gynecologic surgery) should receive multimodal prophylaxis rather than waiting for symptoms to develop.

Management of ICU Delirium and Agitation

Postoperative delirium affects up to 60% of PD patients, yet standard ICU management algorithms are potentially catastrophic.

Safe Approach to Agitated PD Patients:

1. First, Optimize Dopaminergic Therapy:

   • Many "delirious" PD patients are simply having severe "off" episodes with confusion
   • Ensure levodopa doses are on schedule
   • Check for untreated pain, urinary retention, constipation

2. Non-Pharmacologic Interventions:

   • Reorient frequently
   • Ensure sleep-wake cycle (lights, noise control)
   • Early mobilization when feasible
   • Minimize tethering devices (urinary catheters, restraints)

3. Pharmacologic Management - Tiered Approach:

   Tier 1 - Benzodiazepines:

   • Lorazepam 0.5-1 mg IV q4-6h PRN
   • No dopaminergic effects
   • Risk: Respiratory depression, paradoxical agitation in elderly

   Tier 2 - Dexmedetomidine:

   • Alpha-2 agonist, no dopamine antagonism
   • Dose: 0.2-0.7 mcg/kg/hr infusion
   • Advantages: No respiratory depression, preserves arousability
   • Disadvantages: Hypotension, bradycardia; expensive
   • Excellent choice for ICU sedation in mechanically ventilated PD patients

   Tier 3 - Quetiapine (Last Resort):

   • 12.5-25 mg PO/NG nightly
   • Lowest EPS risk among antipsychotics
   • Monitor closely for motor symptom worsening
   • Discontinue immediately if rigidity develops

Hack #4: "PD-Friendly" ICU Order Set:

• Antiemetic: Ondansetron 4 mg IV q8h PRN
• Agitation (Tier 1): Lorazepam 0.5-1 mg IV q4h PRN
• Agitation (Tier 2): Dexmedetomidine gtt if lorazepam insufficient
• HARD STOP: Metoclopramide, Haloperidol, Prochlorperazine
• Alert pharmacy to call MD before dispensing ANY antipsychotic
• Notify neurologist for medication adjustments

Preoperative Patient Education

Pearl #6: Educated patients and families are the best safeguard against medication errors.

Provide written instructions:

• List of prohibited medications (with brand and generic names)
• Statement: "I have Parkinson's disease. I should NEVER receive metoclopramide, haloperidol, or prochlorperazine"
• Emergency contact for neurologist
• Exact home medication schedule

Encourage patients to bring medication bottles to hospital and advocate for continuing home medications rather than substituting hospital formulary alternatives.

---

Conclusion

Perioperative management of Parkinson's disease demands vigilance, planning, and interdisciplinary coordination. The pillars of success are simple: never interrupt dopaminergic therapy, recognize and aggressively treat Parkinson's crises, and scrupulously avoid dopamine antagonists. These principles, applied consistently, can dramatically reduce morbidity and mortality in this vulnerable population.

As critical care physicians, we must serve as institutional champions for PD-safe practices. This includes developing standardized order sets, educating nursing and pharmacy colleagues, and maintaining high suspicion for iatrogenic complications. When in doubt, consult neurology early—but never delay restoration of dopaminergic therapy in suspected PHS or NMS.

The perioperative period tests our ability to balance surgical objectives with neuroprotection. With the strategies outlined in this review, we can navigate these complex cases successfully, ensuring our PD patients emerge from the perioperative period with neurological function preserved and optimized.

---

Key Pearls and Oysters Summary

Pearls:

1. Never abruptly discontinue dopaminergic medications - even 6 hours can trigger crisis
2. Resume oral medications at earliest possible moment, not per arbitrary schedules
3. PHS response is gradual (3-7 days); mortality 3-4% even with optimal care
4. In ambiguous NMS vs PHS cases, treat both: remove neuroleptics AND restore dopamine
5. Prevention of PONV is superior to treatment; use multimodal prophylaxis
6. Patient education is the best medication error prevention

Oysters (Pitfalls):

1. PHS mimics sepsis, NMS, and malignant hyperthermia - think temporal relationships
2. Electronic prescribing rarely flags contraindicated antiemetics in PD
3. "Atypical" antipsychotics are NOT uniformly safe - quetiapine is least risky but still caution
4. Apomorphine + ondansetron = severe hypotension; contraindicated combination

Hacks:

1. Schedule surgery early AM; give first PD med dose with sip of water 1 hour pre-op
2. Create "PD Medication Passport" card attached to chart
3. ICU survival bundle: Restore dopamine + bromocriptine + amantadine + dantrolene (if severe)
4. Develop institution-wide "PD-Friendly" order set with hard stops on contraindicated drugs

---

References

1. Brennan KA, Genever RW. Managing Parkinson's disease during surgery. BMJ. 2010;341:c5718.

2. Schatz IJ, Nixon RA. Parkinson disease and perioperative care: a call for vigilance and coordination of care. Arch Intern Med. 2012;172(17):1338-1339.

3. Furuya R, Hirai A, Andoh T, et al. Successful perioperative management of a patient with Parkinson's disease by enteral levodopa administration under propofol anesthesia. Anesthesiology. 1998;89(1):261-263.

4. Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009;10(1):136-140.

5. Sato K, Hatano T, Yamashiro K, et al. Prognosis of Parkinson's disease: time to stage 3, 4, 5, and to motor fluctuations. Mov Disord. 2006;21(9):1384-1395.

6. Bonuccelli U, Del Dotto P. New pharmacologic horizons in the treatment of Parkinson disease. Neurology. 2006;67(7 Suppl 2):S30-38.

7. Olanow CW, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci. 2000;23(10 Suppl):S117-126.

8. Frucht SJ. Treatment of movement disorder emergencies. Neurotherapeutics. 2014;11(1):208-212.

9. Gurvich T, Cunningham JA. Appropriate use of psychotropic drugs in nursing homes. Am Fam Physician. 2000;61(5):1437-1446.

10. Nicholson G, Pereira AC, Hall GM. Parkinson's disease and anaesthesia. Br J Anaesth. 2002;89(6):904-916.

11. Kageyama T, Nakamura M, Matsuo A, et al. Perioperative management of patients with Parkinson's disease. Masui. 2004;53(10):1117-1123.

12. Müller T, Kuhn W, Büttner T, et al. Subcutaneous apomorphine in Parkinson's disease. J Neural Transm. 2004;111(2):223-230.

13. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease. Neurology. 2006;67(7):1225-1229.

14. Factor SA, Molho ES. Emergency department presentations of patients with Parkinson's disease. Am J Emerg Med. 2000;18(2):209-215.

15. Kipps CM, Fung VS, Grattan-Smith P, et al. Movement disorder emergencies. Mov Disord. 2005;20(3):322-334.

16. Ueda M, Hamamoto M, Nagayama H, et al. Susceptibility to neuroleptic malignant syndrome in Parkinson's disease. Neurology. 1999;52(4):777-781.

17. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989;50(1):18-25.

18. Velamoor VR, Norman RM, Caroff SN, et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 1994;182(3):168-173.

19. Macphee GJ, Stewart DA, Brodie MJ. Modafinil in Parkinson's disease with severe dopaminergic therapy–related somnolence. J Neurol. 2004;251(5):631-632.

20. Apfel CC, Läärä E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting. Anesthesiology. 1999;91(3):693-700.